HeyJaredAlicia Ault
- Indexed articles, last 90 days
- 19
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Florida on Cusp of Measles Outbreak (opens the original)
Read excerpt
A state proposal to eliminate the requirement for the measles, mumps, and rubella (MMR) vaccine to attend school could unleash a widespread measles epidemic in Florida, which is already on the cusp of an outbreak, according to a new study. Researchers at the University of Maryland in College Park, Maryland, used a mathematical model — informed by a 2025 outbreak in Texas and the vaccination rates in Florida — to conclude that measles could become endemic in the state and potentially spread acros
NFID Survey: Adults Confused About Vaccine Recommendations (opens the original)
Read excerpt
Although a majority of Americans believe that vaccines have value, it appears that many are confused about whether they should themselves be receiving shots, according to a new survey conducted for the National Foundation for Infectious Diseases (NFID). At a press briefing in Washington, DC, the organization released survey results and unveiled a new public service campaign, Tame It, that aims to provide guidance and resources for families and healthcare professionals on respiratory illnesses an
Ameluz Approval Seen as Boon to Skin Cancer Armamentarium (opens the original)
Read excerpt
Although it has been used off-label for decades, the photosensitizing agent aminolevulinic acid (ALA) hydrochloride could see greater uptake in the wake of the FDA approval of Biofrontera’s Ameluz for superficial basal cell carcinoma (BCC), said dermatologists. The agency approved Ameluz (ALA hydrochloride) topical gel, 10%, used with Biofrontera’s BF-RhodoLED lamp, for treating superficial BCC in adults — making this the first photodynamic therapy (PDT) drug approved in the US for skin cancer.
FDA Panel Votes on Multicancer Test, Highlights Data Gaps (opens the original)
Read excerpt
An FDA advisory panel said the benefits of Grail’s multicancer detection test outweigh its risks but acknowledged that there is no proof that the diagnostic can reduce mortality. In a series of votes, the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee agreed that Grail’s Galleri multicancer early detection (MCED) test was safe (10 yes, 0 no) and effective (6-4), and that the benefits outweighed the risks (7-2, with one abstention). While the votes on safety
FDA Amps Up Warning on Kybella Adverse Events (opens the original)
Read excerpt
Citing what it called "newly identified risks," the FDA is reinforcing its warnings about adverse events associated with injections of deoxycholic acid (Kybella). In a drug safety communication announcing the update to the deoxycholic acid label, the agency said that adverse events — such as injection site nodules and masses that may or may not have resolved over time — have been identified with approved and unapproved uses. Kybella, manufactured by Allergan Aesthetics (an AbbVie company), was a
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.